Cortechs.ai | New Product from Cortechs.ai: PETQuant for Research Use

New Product from Cortechs.ai: PETQuant for Research Use

PQ_head_reversed-01.pngOn March 9, 2016, Cortechs.ai launched a new research product: PETQuant™. PETQuant provides automated and fast post-acquisition analyses of PET brain studies to quantify subregional tracer binding in native patient brain space, and is compatible with metabolic (FDG) and amyloid-based (florbetapir) tracers.

PETQuant expands the use of NeuroQuant®’s proven and trusted segmentation technology by offering an additional research tool in the evaluation of neurodegenerative dementias, such as Alzheimer’s disease and frontotemporal dementia.

Fast, Accurate and Simplified Quantitative Phenotyping
PETQuant enables clinical researchers to perform post-acquisition analyses of PET brain studies to quantify subregional tracer binding in native patient brain space

Powered by NeuroQuant
PET tracer bindings are accurately localized to brain structures identified by NeuroQuant 3D T1 MRI segmentation

Completely Automatic
PETQuant offers fully automated and consistent results

Fast and Reliable Quantitative Data
In about 10 minutes, PETQuant returns a complete report with color overlay and quantitative information for 46 brain structures, for both left and right hemispheres

Amyloid Deposition and Metabolism Analysis
PETQuant provides two separate reports that correspond to the PET tracer used; choose between metabolic (FDG) and amyloid-based (florbetapir) analysis reports

Simplified and Easy-to-Read
Color-coded graphical presentation simplifies quantitative reads

Available Anytime, Anywhere
Secure, cloud-based system provides access anytime, from virtually anywhere

This version of PETQuant is for research purposes only.

For more information on PETQuant or to schedule a demo, visit cortechs.ai/petquant or contact us.

More Resources

05/18/2025

Cortechs.ai and ALZ-NET Announce Strategic Collaboration to Improve Alzheimer’s Disease Care Through AI-Driven Imaging

This new strategic collaboration aims to enhance the quality of care for people living with Alzheimer’s disease.

05/16/2025

Case Study: NeuroQuant® for ARIA: Monitoring ARIA Progression in Early Alzheimer’s Disease

Dr. Suzie Bash highlights how advanced imaging with NeuroQuant for ARIA supported detection and monitoring of ARIA-E and ARIA-H in an 81-year-old patient.

05/13/2025

Dr. Ana M. Franceschi Joins Cortechs.ai Medical Advisory Board

Neuroimaging thought leader to enhance PET/MRI and dementia research impact through AI-powered tools

05/10/2025

All the Ways to Use the NeuroQuant Custom Report

With the ability to select structures from NeuroQuant’s 70+ structure parcellation atlas, the user has the power to truly personalize patient care!

05/04/2025

Introducing NeuroQuant MS Lesion Dynamics Computation: A Clearer Path to Understanding Disease Progression

Discover how the latest NeuroQuant MS update offers a clearer, more intuitive way to track lesion changes and understand disease progression over time.

05/02/2025

4 Reasons Why Over 1500 Medical Centers Worldwide Trust Cortechs.ai

Trusted by 1500+ medical centers, Cortechs.ai delivers AI-powered imaging tools that enhance diagnostic accuracy and streamline workflows.
Scroll to Top